相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Association of Steroids Use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Fausto Petrelli et al.
CANCERS (2020)
Review: The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs)
Wanhai Ke et al.
THORACIC CANCER (2020)
Successful treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis with triple combination therapy: a case report
Hirofumi Utsumi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
COVID-19 and lung cancer: risks, mechanisms and treatment interactions
Alfredo Addeo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Diffuse alveolar hemorrhage with nivolumab monotherapy
Vickie R. Shannon et al.
RESPIRATORY MEDICINE CASE REPORTS (2020)
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
Chipman R. G. Stroud et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2019)
Management of Immunotherapy-Related Toxicities. Version 1.2019
John A. Thompson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
Yi-Long Wu et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy
Karthik Suresh et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors
Nethanel Asher et al.
ONCOLOGIST (2019)
Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors
Arielle Elkrief et al.
ONCOIMMUNOLOGY (2019)
Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis An Official American Thoracic Society Research Statement
Catherine R. Sears et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors
Jun Fukihara et al.
CLINICAL LUNG CANCER (2019)
The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis
Karthik Suresh et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications
Biagio Ricciuti et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer
Mari Tone et al.
THORACIC CANCER (2019)
Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer
David J. Pinato et al.
JAMA ONCOLOGY (2019)
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis
Biagio Ricciuti et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities
Filipe Martins et al.
LANCET ONCOLOGY (2019)
Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis
Qiang Su et al.
FRONTIERS IN IMMUNOLOGY (2019)
Rapid temporal improvement of pembrolizumab-induced pneumonitis using the anti-TNF-α antibody infliximab
Yutaka Sawai et al.
DRUG DISCOVERIES AND THERAPEUTICS (2019)
A potential mechanism of the onset of acute eosinophilic pneumonia triggered by an anti-PD-1 immune checkpoint antibody in a lung cancer patient
Takayuki Jodai et al.
IMMUNITY INFLAMMATION AND DISEASE (2019)
The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors
Heinz Laubli et al.
ONCOIMMUNOLOGY (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer
Yasuo Oshima et al.
JAMA ONCOLOGY (2018)
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small Cell Lung Cancer
Koji Haratani et al.
JAMA ONCOLOGY (2018)
Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer Benefits and Pulmonary Toxicities
Karthik Suresh et al.
CHEST (2018)
Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors
Karthik Suresh et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Characteristics, incidence, and risk factors of immune checkpoint inhibitor related pneumonitis in patients with non-small cell lung cancer
Jun Yeun Cho et al.
LUNG CANCER (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab
Guacimara Ortega Sanchez et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis
Ke Ma et al.
FRONTIERS IN PHARMACOLOGY (2018)
Ipilimumab and early signs of pulmonary toxicity in patients with metastastic melanoma: a prospective observational study
Daniel Franzen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials
Ricardo Costa et al.
ONCOTARGET (2017)
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
Myriam Delaunay et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Nivolumab-induced Acute Fibrinous and Organizing Pneumonia (AFOP)
Tsukasa Ishiwata et al.
INTERNAL MEDICINE (2017)
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
Jarushka Naidoo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report
Hong Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Calling time on the immunotherapy gold rush
[Anonymous]
LANCET ONCOLOGY (2017)
Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer
Terufumi Kato et al.
LUNG CANCER (2017)
Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis
Tomohiro F. Nishijima et al.
ONCOLOGIST (2017)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Nivolumab-induced interstitial lung disease (ILD) in Japanese patients with non-small cell lung cancer: A study on risk factors using interim results of post-marketing all-case surveillance.
Hirotsugu Kenmotsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
L. Khoja et al.
ANNALS OF ONCOLOGY (2017)
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer
Monica Khunger et al.
CHEST (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions
Jessica C. Hassel et al.
CANCER TREATMENT REVIEWS (2017)
Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
Morganna Freeman-Keller et al.
CLINICAL CANCER RESEARCH (2016)
Management of toxicities of immune checkpoint inhibitors
Lavinia Spain et al.
CANCER TREATMENT REVIEWS (2016)
PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course
Mizuki Nishino et al.
CLINICAL CANCER RESEARCH (2016)
Immune-mediated respiratory adverse events of checkpoint inhibitors
Samer Tabchi et al.
CURRENT OPINION IN ONCOLOGY (2016)
Evaluation of efficacy and safety of different pembrolizumab dose/schedules in treatment of non-small-cell lung cancer and melanoma: a systematic review
Omar Abdel-Rahman
IMMUNOTHERAPY (2016)
Nivolumab-induced organizing pneumonia in a melanoma patient
Tasuku Sano et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2016)
Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial
M. -J. Ahn et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1
Joohee Sul et al.
ONCOLOGIST (2016)
Severe pneumonitis after nivolumab treatment in a patient with melanoma
Satoshi Watanabe et al.
ALLERGOLOGY INTERNATIONAL (2016)
Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer
Mizuki Nishino et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
Omar Abdel-Rahman et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2016)
Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer A Systematic Review and Meta-analysis
Mizuki Nishino et al.
JAMA ONCOLOGY (2016)
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors A Review
Claire F. Friedman et al.
JAMA ONCOLOGY (2016)
Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study
Viktor H. Koelzer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance
Yanping Xiao et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
分享论文
